PMP22 and hereditary neuropathy with liability to pressure palsies: Considering the very high likelihood of HNPP diagnosis because of the typical history and lower cost of targeted genetic analysis compared to whole exome sequencing, a targeted gene analysis for the PMP22 gene was sent which showed a heterozygous deletion, confirming the diagnosis of HNPP. Steroids were tapered over the next six weeks and stopped.